Figure 4

Western blot of PPARγ and MAP kinase p38 in mammary tumours. Western blot of PPARγ and MAP kinase p38 levels in mammary tumours after treatment with Rosiglitazone and Cisplatin in DMBA induced breast cancer rats. Where, lane a: Cancer Control, lane b: Rosiglitazone, lane c: Cisplatin and lane d: Rosiglitazone pre-treatment. Results were normalized with respect to Actin. Similar results were obtained in three independent set of experiments. All the values were represented as Mean ± S.E.M. (n = 3), **P < 0.01; * P < 0.05; a Vs Cancer Control and b Vs Cisplatin.